prednisone has been researched along with Leukemia, Pre-B-Cell in 61 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the ALL-BFM studies for treatment of acute lymphoblastic leukemia, reduction of leukemic blasts in peripheral blood after a one-week prednisone pre-phase - the so-called prednisone response - has been used for risk stratification since the 1980s and has been one of the most relevant factors for identification of high-risk patients." | 2.78 | Prediction of outcome by early response in childhood acute lymphoblastic leukemia. ( Attarbaschi, A; Beier, R; Lauten, M; Möricke, A; Niggli, F; Odenwald, E; Schrappe, M; Stanulla, M; Zimmermann, M, 2013) |
| "A total of 119 children (1990-95) with acute lymphoblastic leukemia (ALL) B-lineage either CD10+ or CD10- were registered into a single non-randomized chemotherapy protocol." | 2.68 | B-lineage acute lymphoblastic leukemia of childhood. An institutional experience. ( Cardenas-Cardos, R; Gómez-Martínez, R; Leal-Leal, C; Meza-Coria, C; Navarro-Alegría, I; Rivera-Luna, R; Vega-Vega, L, 1997) |
| "Acute myelofibrosis (AMF), as defined by an acute panmyelopathy associated with marked megakaryocytic hyperplasia and marrow fibrosis, appears to be a stem cell disorder." | 2.39 | Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature. ( Dunphy, CH; Kitchen, S; Saravia, O; Velasquez, WS, 1996) |
| "Besides, the PLK4 expression in childhood ALL patients was also determined at day 15 after the initiation of induction therapy (D15)." | 1.91 | Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients. ( Xu, J; Zhao, L, 2023) |
| "Risperidone is an effective short-term pharmacologic agent for controlling steroid-related psychiatric adverse effects when cessation or dose reduction of steroid therapy is not an option." | 1.36 | Concurrent treatment of steroid-related mood and psychotic symptoms with risperidone. ( Dahl, G; Shaw, RJ; Tzuang, D; Ularntinon, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (19.67) | 18.2507 |
| 2000's | 16 (26.23) | 29.6817 |
| 2010's | 28 (45.90) | 24.3611 |
| 2020's | 5 (8.20) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, J | 1 |
| Zhao, L | 1 |
| Rausch, CR | 1 |
| Jabbour, EJ | 1 |
| Kantarjian, HM | 2 |
| Kadia, TM | 1 |
| Bravo-Perez, C | 1 |
| Pajares, I | 1 |
| Muiña, B | 1 |
| Escobar, H | 1 |
| Amigo, ML | 1 |
| Garcia-Malo, MD | 1 |
| Garcia, J | 1 |
| Rodriguez-Pinilla, SM | 1 |
| Piris, MA | 1 |
| Ortuño, FJ | 1 |
| Salzer, WL | 2 |
| Burke, MJ | 1 |
| Devidas, M | 5 |
| Dai, Y | 2 |
| Hardy, KK | 2 |
| Kairalla, JA | 2 |
| Gore, L | 1 |
| Hilden, JM | 1 |
| Larsen, E | 4 |
| Rabin, KR | 1 |
| Zweidler-McKay, PA | 1 |
| Borowitz, MJ | 3 |
| Wood, B | 2 |
| Heerema, NA | 3 |
| Carroll, AJ | 2 |
| Winick, N | 3 |
| Carroll, WL | 5 |
| Raetz, EA | 3 |
| Loh, ML | 4 |
| Hunger, SP | 4 |
| Dai, Q | 1 |
| Zhang, G | 1 |
| Yang, H | 1 |
| Wang, Y | 2 |
| Ye, L | 1 |
| Peng, L | 1 |
| Shi, R | 1 |
| Guo, S | 1 |
| He, J | 1 |
| Jiang, Y | 1 |
| Chen, S | 1 |
| Maloney, K | 1 |
| Mattano, L | 1 |
| Carroll, A | 1 |
| Gastier-Foster, JM | 2 |
| Willman, C | 1 |
| Raetz, E | 1 |
| Embry, L | 1 |
| Helian, S | 1 |
| Armstrong, D | 1 |
| Hunger, S | 1 |
| Yang, W | 1 |
| Relling, MV | 1 |
| Noll, RB | 1 |
| Landmann, E | 1 |
| Burkhardt, B | 1 |
| Zimmermann, M | 4 |
| Meyer, U | 1 |
| Woessmann, W | 1 |
| Klapper, W | 1 |
| Wrobel, G | 1 |
| Rosolen, A | 2 |
| Pillon, M | 2 |
| Escherich, G | 1 |
| Attarbaschi, A | 5 |
| Beishuizen, A | 1 |
| Mellgren, K | 1 |
| Wynn, R | 1 |
| Ratei, R | 4 |
| Plesa, A | 1 |
| Schrappe, M | 6 |
| Reiter, A | 1 |
| Bergeron, C | 1 |
| Patte, C | 1 |
| Bertrand, Y | 1 |
| Thakkar, D | 1 |
| Singh, Y | 1 |
| Yadav, SP | 1 |
| DiNofia, AM | 1 |
| Seif, AE | 1 |
| Li, Y | 2 |
| Hall, M | 1 |
| Huang, YV | 1 |
| Cahen, V | 1 |
| Winick, NJ | 3 |
| Fisher, BT | 1 |
| Larsen, EC | 1 |
| Aplenc, R | 1 |
| Saghir, S | 1 |
| Meskini, T | 1 |
| Ettair, S | 1 |
| Erreimi, N | 1 |
| Mouane, N | 1 |
| Möricke, A | 4 |
| Lauten, M | 2 |
| Beier, R | 2 |
| Odenwald, E | 2 |
| Stanulla, M | 2 |
| Niggli, F | 3 |
| Schabath, R | 1 |
| Karawajew, L | 1 |
| Ludwig, WD | 1 |
| Wiegering, V | 1 |
| Frank, J | 1 |
| Freudenberg, S | 1 |
| Morbach, H | 1 |
| Schlegel, PG | 1 |
| Eyrich, M | 1 |
| Winkler, B | 1 |
| Huang, Q | 1 |
| Berenguer-Potenciano, M | 1 |
| Villora-Morcillo, N | 1 |
| Nunez-Enamorado, N | 1 |
| Perez-Alonso, V | 1 |
| Camacho-Salas, A | 1 |
| Simon-De Las Heras, R | 1 |
| Afsar, FS | 1 |
| Ozek, G | 1 |
| Vergin, C | 1 |
| Wood, BL | 1 |
| Nachman, JB | 1 |
| Willman, CL | 1 |
| Matsuda, I | 1 |
| Hirota, S | 1 |
| Kim, TK | 1 |
| Xu, ML | 1 |
| Podoltsev, NA | 1 |
| Prebet, T | 1 |
| Barbarotta, L | 1 |
| Amin, K | 1 |
| Kasberg, S | 1 |
| Roche, K | 1 |
| Stahl, M | 1 |
| Gore, SD | 1 |
| Zeidan, AM | 1 |
| Thomas, DA | 1 |
| O'Brien, S | 1 |
| Jorgensen, JL | 1 |
| Cortes, J | 1 |
| Faderl, S | 1 |
| Garcia-Manero, G | 1 |
| Verstovsek, S | 1 |
| Koller, C | 1 |
| Pierce, S | 1 |
| Huh, Y | 1 |
| Wierda, W | 1 |
| Keating, MJ | 1 |
| Dworzak, MN | 3 |
| Schumich, A | 2 |
| Printz, D | 1 |
| Pötschger, U | 1 |
| Husak, Z | 1 |
| Basso, G | 3 |
| Gaipa, G | 2 |
| Mann, G | 2 |
| Gadner, H | 3 |
| Han, Y | 1 |
| Xue, Y | 1 |
| Zhang, J | 1 |
| Wu, Y | 1 |
| Pan, J | 1 |
| Shen, J | 1 |
| Dai, H | 1 |
| Bai, S | 1 |
| Papayannidis, C | 1 |
| Derenzini, E | 1 |
| Iacobucci, I | 1 |
| Curti, A | 1 |
| Paolini, S | 1 |
| Cilloni, D | 1 |
| Baccarani, M | 1 |
| Martinelli, G | 1 |
| Pichler, H | 1 |
| Teigler-Schlegel, A | 1 |
| Nebral, K | 1 |
| König, M | 1 |
| Inthal, A | 1 |
| Krehan, D | 1 |
| Janousek, D | 1 |
| Harbott, J | 1 |
| Strehl, S | 1 |
| Haas, OA | 1 |
| Panzer-Grümayer, R | 1 |
| Mahadeo, KM | 1 |
| Dhall, G | 1 |
| Panigrahy, A | 1 |
| Lastra, C | 1 |
| Ettinger, LJ | 1 |
| Ularntinon, S | 1 |
| Tzuang, D | 1 |
| Dahl, G | 1 |
| Shaw, RJ | 1 |
| Chen, X | 1 |
| Zhang, Y | 1 |
| Lei, P | 1 |
| Zhai, Y | 1 |
| Liu, L | 1 |
| Meeker, ND | 1 |
| Cherry, AM | 1 |
| Bangs, CD | 1 |
| Frazer, JK | 1 |
| Kaygusuz, I | 1 |
| Toptas, T | 1 |
| Guven, A | 1 |
| Firatli-Tuglular, T | 1 |
| Tecimer, T | 1 |
| Bayik, M | 1 |
| Aricò, M | 1 |
| Locatelli, F | 2 |
| Citterio, M | 1 |
| Micalizzi, C | 1 |
| Testi, AM | 1 |
| Barisone, E | 1 |
| Nardi, M | 1 |
| Lombardi, A | 1 |
| Rondelli, R | 1 |
| Shiratori, S | 1 |
| Kondo, T | 1 |
| Fujisawa, S | 1 |
| Kubota, K | 1 |
| Kosugi, M | 1 |
| Shono, Y | 1 |
| Sugita, J | 1 |
| Fujimoto, K | 1 |
| Nishio, M | 1 |
| Tanaka, J | 1 |
| Koike, T | 1 |
| Matsuno, Y | 1 |
| Matsuno, K | 1 |
| Asaka, M | 1 |
| Imamura, M | 1 |
| Shalapour, S | 1 |
| Hof, J | 1 |
| Kirschner-Schwabe, R | 1 |
| Bastian, L | 1 |
| Eckert, C | 1 |
| Prada, J | 1 |
| Henze, G | 1 |
| von Stackelberg, A | 1 |
| Seeger, K | 1 |
| Bisaccia, E | 1 |
| Palangio, M | 1 |
| Gonzalez, J | 1 |
| Meissner, B | 1 |
| Niemeyer, C | 1 |
| Riehm, H | 2 |
| Esin, S | 1 |
| Tarim, E | 1 |
| Abali, H | 1 |
| Kardes, O | 1 |
| Kocer, EN | 1 |
| Alkan, O | 1 |
| Williams, MS | 1 |
| Ali, N | 1 |
| Nonaka, D | 1 |
| Bloor, AJ | 1 |
| Somervaille, TC | 1 |
| Tutor, O | 1 |
| Díaz, MA | 1 |
| Ramírez, M | 1 |
| Algara, P | 1 |
| Madero, L | 1 |
| Martínez, P | 1 |
| McCarthy, LJ | 1 |
| Houseworth, J | 1 |
| Danielson, C | 1 |
| Rao, RD | 1 |
| Swanson, JW | 1 |
| Dejesus, RS | 1 |
| Hunt, CH | 1 |
| Tefferi, A | 1 |
| Mantadakis, E | 1 |
| Smith, AK | 1 |
| Hynan, L | 1 |
| Kamen, BA | 1 |
| Comeau, TB | 1 |
| Phillips, DL | 1 |
| Perrotta, S | 1 |
| Conte, ML | 1 |
| La Manna, A | 1 |
| Indolfi, P | 1 |
| Rossi, F | 1 |
| Nobili, B | 1 |
| Layden, BT | 1 |
| Joseph, M | 1 |
| Tallman, MS | 1 |
| Platanias, LC | 1 |
| Aliprandi, S | 1 |
| Migliavacca, M | 1 |
| Vallinoto, C | 1 |
| Maglia, O | 1 |
| Faini, A | 1 |
| Veltroni, M | 1 |
| Husak, D | 1 |
| Biondi, A | 2 |
| Gururangan, S | 1 |
| Horner, M | 1 |
| Rodman, JH | 1 |
| Marina, NM | 1 |
| Pullen, J | 2 |
| Boyett, J | 1 |
| Shuster, J | 2 |
| Crist, W | 2 |
| Land, V | 1 |
| Frankel, L | 2 |
| Iyer, R | 1 |
| Backstrom, L | 1 |
| van Eys, J | 1 |
| Harris, M | 1 |
| Dunphy, CH | 1 |
| Kitchen, S | 1 |
| Saravia, O | 1 |
| Velasquez, WS | 1 |
| Conter, V | 1 |
| D'Angelo, P | 1 |
| Rizzari, C | 1 |
| Jankovic, M | 1 |
| Dampier, C | 1 |
| Masera, G | 2 |
| Johnson, FL | 1 |
| Soslow, RA | 1 |
| Davis, RE | 1 |
| Warnke, RA | 1 |
| Cleary, ML | 1 |
| Kamel, OW | 1 |
| Rivera-Luna, R | 1 |
| Cardenas-Cardos, R | 1 |
| Leal-Leal, C | 1 |
| Navarro-Alegría, I | 1 |
| Meza-Coria, C | 1 |
| Gómez-Martínez, R | 1 |
| Vega-Vega, L | 1 |
| Lenormand, B | 1 |
| Béné, MC | 1 |
| Lesesve, JF | 1 |
| Bastard, C | 1 |
| Tilly, H | 1 |
| Lefranc, MP | 1 |
| Faure, GC | 1 |
| Garand, R | 1 |
| Falkenrodt, A | 1 |
| Kandel, G | 1 |
| Solary, E | 1 |
| Maynadié, M | 1 |
| Callat, MP | 1 |
| Thouret, F | 1 |
| Monconduit, M | 1 |
| Vannier, JP | 1 |
| Bueno, J | 1 |
| Zuazu, J | 1 |
| Villalba, T | 1 |
| Julià, A | 1 |
| Mathew, S | 1 |
| Lorsbach, RB | 1 |
| Shearer, P | 1 |
| Sandlund, JT | 1 |
| Raimondi, SC | 1 |
| Kelleher, JF | 1 |
| Monteleone, PM | 1 |
| Steele, DA | 1 |
| Gang, DL | 1 |
| Angelides, AG | 1 |
| Bassan, R | 1 |
| Rohatiner, AZ | 1 |
| Lerede, T | 1 |
| Di Bona, E | 1 |
| Rambaldi, A | 1 |
| Pogliani, E | 1 |
| Rossi, G | 1 |
| Fabris, P | 1 |
| Morandi, S | 1 |
| Casula, P | 1 |
| Carter, M | 1 |
| Lambertenghi-Deliliers, G | 1 |
| Lister, TA | 1 |
| Barbui, T | 1 |
| Willemse, MJ | 1 |
| Seriu, T | 1 |
| Hettinger, K | 1 |
| d'Aniello, E | 1 |
| Hop, WC | 1 |
| Panzer-Grümayer, ER | 1 |
| Kamps, WA | 1 |
| Bartram, CR | 1 |
| van Dongen, JJ | 1 |
| Look, T | 1 |
| Borowitz, M | 1 |
| Behm, F | 1 |
| Bowman, P | 1 |
| Krance, R | 1 |
| Steuber, P | 1 |
| Rudzka, E | 1 |
| Holowiecki, J | 1 |
| Kachel, L | 1 |
| Lawniczek, T | 1 |
| Pajak, J | 1 |
| Bisail, M | 1 |
| Cassisa, L | 1 |
| Manca, M | 1 |
| Casula, S | 1 |
| Fele, G | 1 |
| Malavasi, A | 1 |
| De Salvo Cardullo, L | 1 |
| Weir Madina, J | 1 |
| Gómez Sánchez, O | 1 |
| Plumacher, Z | 1 |
| Salas, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations[NCT02883049] | Phase 3 | 5,937 participants (Actual) | Interventional | 2012-02-29 | Active, not recruiting | ||
| Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL)[NCT00275106] | Phase 3 | 600 participants (Anticipated) | Interventional | 2004-09-30 | Terminated (stopped due to Withdrawn due to an excess of toxic deaths) | ||
| High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)[NCT00075725] | Phase 3 | 3,154 participants (Actual) | Interventional | 2003-12-29 | Completed | ||
| A Prospective Study Evaluating the Efficacy of the Allogeneic Hematopoietic Cell Transplantation With Antithymocyte Globulin (ATG)-Based Conditioning of Adult Acute Lymphoblastic Leukemia in First / Second Complete Hematologic Remission[NCT02428517] | 20 participants (Actual) | Observational | 2015-04-30 | Terminated (stopped due to The PI resigned the institute, and the rest investigators at the institute decided to terminate the study.) | |||
| Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia[NCT01429610] | Phase 2 | 78 participants (Actual) | Interventional | 2011-11-30 | Active, not recruiting | ||
| ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia[NCT00430118] | Phase 3 | 4,559 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia[NCT00114348] | Phase 4 | 338 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Event Free Probability. (NCT00075725)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Dexamethasone and Capizzi Methotrexate Patients < 10 Years | 83.2 |
| Dexamethasone, High Dose Methotrexate (Non Randomly Assigned) | 81.6 |
| Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old | 69.1 |
| Dexamethasone, High Dose Methotrexate (IM) < 10 Years | 91.2 |
| Prednisone, Capizzi Methotrexate <10 Years | 82.1 |
| Prednisone, Capezzi Methotrexate >= 10 Years | 73.5 |
| Predisone and High Dose Methotrexate < 10 Yrs Old | 80.8 |
| Prenisone and High Dose Methotrexate >=10 Years | 75.8 |
| Dexamethasone, High Dose Methotrexate (IM) >= 10 Years | 77.0 |
| Prenisone, Capezzi Methotrexate (Down's Syndrome) | 61.8 |
| Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random) | 44.4 |
Bone marrow status is defined as: M1: < 5% lymphoblasts; M2: 5-25% lymphoblasts; M3: > 25% lymphoblasts. Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: Day 29
| Intervention | participants (Number) |
|---|---|
| Dexamethasone and Capizzi Methotrexate Patients < 10 Years | 182 |
| Dexamethasone, High Dose Methotrexate (Non Randomly Assigned) | 72 |
| Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old | 198 |
| Dexamethasone, High Dose Methotrexate (IM) < 10 Years | 188 |
| Prednisone, Capizzi Methotrexate <10 Years | 195 |
| Prednisone, Capezzi Methotrexate >= 10 Years | 471 |
| Prednisone and High Dose Methotrexate < 10 Yrs Old | 190 |
| Prednisone and High Dose Methotrexate >=10 Years | 479 |
| Dexamethasone, High Dose Methotrexate (IM) >= 10 Years | 208 |
| Prednisone, Capezzi Methotrexate (Down's Syndrome) | 25 |
| Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random) | 3 |
| Prednisone and High Dose Methotrexate (Non Randomly Assigned) | 18 |
Bone marrow status is defined as: M1: < 5% lymphoblasts; M2: 5-25% lymphoblasts; M3: > 25% lymphoblasts. Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: Day 29
| Intervention | participants (Number) |
|---|---|
| Dexamethasone and Capizzi Methotrexate Patients < 10 Years | 26 |
| Dexamethasone, High Dose Methotrexate (Non Randomly Assigned) | 12 |
| Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old | 43 |
| Dexamethasone, High Dose Methotrexate (IM) < 10 Years | 14 |
| Prednisone, Capizzi Methotrexate <10 Years | 16 |
| Prednisone, Capezzi Methotrexate >= 10 Years | 95 |
| Prednisone and High Dose Methotrexate < 10 Yrs Old | 17 |
| Prednisone and High Dose Methotrexate >=10 Years | 98 |
| Dexamethasone, High Dose Methotrexate (IM) >= 10 Years | 39 |
| Prednisone, Capezzi Methotrexate (Down's Syndrome) | 3 |
| Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random) | 3 |
| Prednisone and High Dose Methotrexate (Non Randomly Assigned) | 3 |
Bone marrow MRD status is defined as negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Dexamethasone and Capizzi Methotrexate Patients < 10 Years | 86.4 |
| Dexamethasone, High Dose Methotrexate (Non Randomly Assigned) | 93.6 |
| Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old | 80.5 |
| Dexamethasone, High Dose Methotrexate (IM) < 10 Years | 93.1 |
| Prednisone, Capizzi Methotrexate <10 Years | 86.5 |
| Prednisone, Capezzi Methotrexate >= 10 Years | 83.4 |
| Prednisone and High Dose Methotrexate < 10 Yrs Old | 84.2 |
| Prednisone and High Dose Methotrexate >=10 Years | 83.9 |
| Dexamethasone, High Dose Methotrexate (IM) >= 10 Years | 85.3 |
| Prednisone, Capezzi Methotrexate (Down's Syndrome) | 74.4 |
| Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random) | 25 |
Bone marrow MRD status is defined as negative with < .01 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Dexamethasone and Capizzi Methotrexate Patients < 10 Years | 95.4 |
| Dexamethasone, High Dose Methotrexate (Non Randomly Assigned) | 92.9 |
| Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old | 87.4 |
| Dexamethasone, High Dose Methotrexate (IM) < 10 Years | 98.1 |
| Prednisone, Capizzi Methotrexate <10 Years | 93.3 |
| Prednisone, Capizzi Methotrexate >= 10 Years | 90.2 |
| Prednisone and High Dose Methotrexate < 10 Yrs Old | 94.5 |
| Prednisone and High Dose Methotrexate >=10 Years | 90.5 |
| Dexamethasone, High Dose Methotrexate (IM) >= 10 Years | 91.6 |
| Prednisone, Capizzi Methotrexate (Down's Syndrome) | 78.3 |
| Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random) | 25.0 |
Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Dexamethasone and Capizzi Methotrexate Patients < 10 Years | 66.5 |
| Dexamethasone, High Dose Methotrexate (Non Randomly Assigned) | 43.3 |
| Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old | 35.4 |
| Dexamethasone, High Dose Methotrexate (IM) < 10 Years | 80 |
| Prednisone, Capizzi Methotrexate <10 Years | 34.7 |
| Prednisone, Capizzi Methotrexate >= 10 Years | 39 |
| Prednisone and High Dose Methotrexate < 10 Yrs Old | 55 |
| Prednisone and High Dose Methotrexate >=10 Years | 47.8 |
| Dexamethasone, High Dose Methotrexate (IM) >= 10 Years | 49.4 |
Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 Years
| Intervention | percentage of participants (Number) |
|---|---|
| Dexamethasone and Capizzi Methotrexate Patients < 10 Years | 79.2 |
| Dexamethasone, High Dose Methotrexate (Non Randomly Assigned) | 69.9 |
| Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old | 65.6 |
| Dexamethasone, High Dose Methotrexate (IM) < 10 Years | 86.2 |
| Prednisone, Capizzi Methotrexate <10 Years | 93.8 |
| Prednisone, Capizzi Methotrexate >= 10 Years | 63.1 |
| Predisone and High Dose Methotrexate < 10 Yrs Old | 84.2 |
| Prednisone and High Dose Methotrexate >=10 Years | 73.6 |
| Dexamethasone, High Dose Methotrexate (IM) >= 10 Years | 74.6 |
2 reviews available for prednisone and Leukemia, Pre-B-Cell
| Article | Year |
|---|---|
Precursor B cell lymphoblastic lymphoma presenting as a solitary bone tumor: a case report and review of the literature.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bon | 2010 |
Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Bone Marrow; Chro | 1996 |
15 trials available for prednisone and Leukemia, Pre-B-Cell
| Article | Year |
|---|---|
Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Dexamethasone; Female; Humans; Hy | 2020 |
Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group.
Topics: Adrenal Cortex Hormones; Adult Survivors of Child Adverse Events; Age Factors; Antineoplastic Combin | 2017 |
Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.
Topics: Adolescent; Child; Child, Preschool; Dexamethasone; Europe; Female; Humans; Infant; Male; Precursor | 2017 |
Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; | 2018 |
Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Bone Marrow; Cell Lineage; Chi | 2013 |
Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Lineage; Child; Child | 2013 |
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.
Topics: Antineoplastic Agents; Asparaginase; Child; Child, Preschool; Dexamethasone; Disease-Free Survival; | 2015 |
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineop | 2008 |
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineop | 2008 |
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineop | 2008 |
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineop | 2008 |
Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2010 |
High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2011 |
Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Bone Marrow; Child; Child, | 2012 |
Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Diseases; Cyclo | 1993 |
B-lineage acute lymphoblastic leukemia of childhood. An institutional experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Presch | 1997 |
PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe dEtude Immunologique des Leucémies.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bur | 1998 |
Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymph | 1992 |
44 other studies available for prednisone and Leukemia, Pre-B-Cell
| Article | Year |
|---|---|
Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients.
Topics: Biomarkers; Humans; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic L | 2023 |
Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2020 |
Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma.
Topics: Abnormal Karyotype; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Asparaginase | 2020 |
Clinical features and outcome of pediatric acute lymphoblastic leukemia with low peripheral blood blast cell count at diagnosis.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Child; Child, Preschool; Female; Humans; Infant; Infant | 2021 |
Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neoplasms; Cere | 2017 |
Drug Rash, Eosinophilia, Systemic Symptoms (DRESS) in a Child With Acute Lymphoblastic Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Daunorubicin; Drug H | 2018 |
[Weber-Christian's disease: a preleukemic disorder?]
Topics: Anti-Inflammatory Agents; Biopsy; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Infant | 2019 |
Impaired B-cell reconstitution in children after chemotherapy for standard or medium risk acute precursor B-lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Cell Activating Factor; | 2014 |
Cocirculating precursor B acute lymphoblastic leukemia and chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2013 |
[Therapeutic response to pyridoxine and pyridostigmine in a paediatric case of severe peripheral and cranial polyneuropathy due to vincristine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blepharoptosis; Cranial Nerve Diseases | 2015 |
Half-and-half nails in a pediatric patient after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Diagnosis, Differ | 2015 |
Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combin | 2015 |
Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.
Topics: Aged, 80 and over; Antibodies, Bispecific; Antineoplastic Agents; Antineoplastic Combined Chemothera | 2016 |
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combi | 2009 |
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combi | 2009 |
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combi | 2009 |
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combi | 2009 |
Translocation (14;14)(q11;q32) with simultaneous involvement of the IGH and CEBPE genes in B-lineage acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CCAAT-Enhancer-Binding Pro | 2008 |
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity via direct end
Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cytara | 2010 |
Concurrent treatment of steroid-related mood and psychotic symptoms with risperidone.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Hormonal; Antipsychotic Agents; Child; Dexa | 2010 |
Biphenotypic hematologic malignancy: a case report of the 8p11 myeloproliferative syndrome in a child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Chromosomes, Human, Pair 13; Chromosomes, Hum | 2010 |
A pediatric B lineage leukemia with coincident MYC and MLL translocations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Cytarabine; Doxo | 2011 |
Long-term results of AIEOP-8805 protocol for acute B-cell lymphoblastic leukemia of childhood.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2011 |
c-myc rearrangement in B-cell lymphoblastic lymphoma with the involvement of multiple extranodal lesions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Choroid; Cyclophosphamide; Doxorubicin; Female; Gene | 2011 |
Long-term extracorporeal photochemotherapy in a pediatric patient with refractory sclerodermatous chronic graft-versus-host disease.
Topics: Adolescent; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2011 |
Management of precursor B-lymphoblastic lymphoma/leukaemia of thoracic spine in a pregnancy presenting with acute paraplegia.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cesar | 2012 |
Fatal invasive aspergillosis of the larynx.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Aspergillosis; Consolidation Chemother | 2013 |
Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclin-Depend | 2002 |
Transfusion medicine illustrated. White out: extreme leukocytosis treated with WBC reduction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cytarabine; Daunor | 2002 |
Methotrexate induced seizures associated with acute reversible magnetic resonance imaging (MRI) changes in a patient with acute lymphoblastic leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase | 2002 |
Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone | 2002 |
Chemotherapy dosing with elevated liver function test results in acute leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Humans; Liver; L | 2005 |
Membranous glomerulopathy in children given allogeneic hematopoietic stem cell transplantation.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Asparagin | 2005 |
Acute lymphoblastic leukemia in a patient with chronic cyanoacrylate exposure.
Topics: Adhesives; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyanoacrylates; Cycl | 2007 |
Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells.
Topics: Adolescent; Antigens, CD34; Cell Culture Techniques; Child; Child, Preschool; Female; Flow Cytometry | 2008 |
Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child, Preschool; Cystic Fibrosis; Cyt | 1994 |
High-dose cytosine arabinoside and fractionated total body irradiation as a preparative regimen for the treatment of children with acute lymphoblastic leukemia and Down syndrome by allogeneic bone marrow transplantation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child, Pres | 1996 |
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Neoplasms; Child; Cisplati | 1996 |
[Acute leukemia in Jehovah's Witnesses].
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blood Transfusion; Chri | 1999 |
Double minute chromosomes and c-MYC amplification in a child with secondary myelodysplastic syndrome after treatment for acute lymphoblastic leukemia.
Topics: Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combined Chemotherapy Protocol | 2000 |
Hepatic dysfunction as the presenting feature of acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Child, Preschool; | 2001 |
Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cohort Studies; Disease-Free Survival; F | 2002 |
Skin manifestation of extramedullary relapse in adult with acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; C | 1991 |
[Discordance between clinical and immunological aspects in a case of chronic B-type lymphoproliferative syndrome].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Chronic Disease; Cyclophosphami | 1991 |
[Granular CALLA-positive acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Child, Preschool; C | 1990 |